{"id":11067,"date":"2024-01-07T12:59:00","date_gmt":"2024-01-07T11:59:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=11067"},"modified":"2025-08-08T13:04:40","modified_gmt":"2025-08-08T11:04:40","slug":"p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/","title":{"rendered":"P727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0"},"content":{"rendered":"
\n

E Papathanasiou<\/a>\u00a0,\u00a0P Markopoulos<\/a>\u00a0,\u00a0M Tzouvala<\/a>\u00a0,\u00a0A Ioannou<\/a>\u00a0,\u00a0E Tsironi<\/a>\u00a0,\u00a0E Zacharopoulou<\/a>\u00a0,\u00a0M Tzakri<\/a>\u00a0,\u00a0E Pantelakis<\/a>\u00a0,\u00a0G Leonidakis<\/a>\u00a0,\u00a0G Bamias<\/a>\u00a0,\u00a0S Michopoulos<\/a>\u00a0,\u00a0E Zampeli<\/a><\/p>\n<\/div>\n\n

\n

Journal of Crohn’s and Colitis<\/em>, Volume 18, Issue Supplement_1, January 2024, Pages i1356\u2013i1357,\u00a0https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0857<\/a><\/p>\n<\/div>\n\n

\n

Background: Selective depletion of myeloid lineage leucocytes by adsorptive granulocyte and monocyte apheresis (GMA) with Adacolumn\u00a0\u00ae<\/sup>\u00a0was introduced as a nonpharmacologic treatment for ulcerative colitis (UC) in 2000. It has been reported that GMA may be effective in combination with immunosuppressive treatment in a subset of patients. \u03a4he purpose of our study is the evaluation of the effectiveness and safety of GMA as a complementary treatment in patients with refractory ulcerative colitis.<\/p>\n<\/div>\n\n

\n

Methods: Prospective data collection of a patient cohort with refractory UC receiving Adacolumn\u00a0\u00ae<\/sup>\u00a0as an adjunct to their medical treatment. The therapeutic protocol has 2 phases: The induction phase entails two sessions per week for at least 3 weeks. The maintenance includes one weekly session for one month, one session every 15 days for one the next month, and monthly sessions thereafter. The patients\u2019 medical treatment was maintained during the sessions. As a failure to GMA was considered the need for colectomy, the switch to a different treatment and inability to discontinue steroids. Response was evaluated after completion of at least 6 sessions of GMA.<\/p>\n<\/div>\n\n

\n

Results: Ten patients with refractory UC were offered Adacolumn\u00ae<\/sup>\u00a0between February 2021 and September 2023. Mean age was 39.6 years (22-61years). All patients had failed at least one biologic treatment and two-thirds two biologics. Their treatment which was maintained during GMA was: tofacitinib 10mg bid for 4 patients, ustekinumab 90mg sc every 8 weeks for 3, vedolizumab 300 mg every 8 weeks for 2, and corticosteroids 16mg for one. The median duration of treatment was 5.1 months (2-13 months), while the median number of sessions was 16 (6-45). Clinical and endoscopic remission was achieved in two cases (20%), after 13 sessions for both (in brackets in the Table) whereas two patients (20%) responded clinically according to partial Mayo score. Treatment failure was documented for 6 patients (60%) after 6-45 sessions. Patient number 4 performed 45 sessions in different hospitals because he was reluctant to be operated. Three underwent colectomy and three discontinued due to non-response. No adverse effects were observed. The initial median of partial Mayo score was 6 (5-9) while at the end of the evaluation was 4.5 (0-9). Table 1 summarizes the results of our study.<\/p>\n<\/div>\n\n

\n

Conclusion<\/p>\n<\/div>\n\n

\n

1) GMA may be beneficial as an adjunct to biologics in refractory to medical treatment UC patients.<\/p>\n<\/div>\n\n

\n

2) Interestingly, all patients on tofacitinib showed a favorable response after the addition of GMA.<\/p>\n<\/div>\n\n

\n

This observation may help define a subset of UC patients who may benefit the most.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

E Papathanasiou\u00a0,\u00a0P Markopoulos\u00a0,\u00a0M Tzouvala\u00a0,\u00a0A Ioannou\u00a0,\u00a0E Tsironi\u00a0,\u00a0E Zacharopoulou\u00a0,\u00a0M Tzakri\u00a0,\u00a0E Pantelakis\u00a0,\u00a0G Leonidakis\u00a0,\u00a0G Bamias\u00a0,\u00a0S Michopoulos\u00a0,\u00a0E Zampeli Journal of Crohn’s and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1356\u2013i1357,\u00a0https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0857 Background: Selective depletion of myeloid lineage leucocytes by adsorptive granulocyte and monocyte apheresis (GMA) with Adacolumn\u00a0\u00ae\u00a0was introduced as a nonpharmacologic treatment for ulcerative colitis (UC) in 2000. It has […]<\/p>\n","protected":false},"template":"","scientific_tags":[851,303,157,424,97,461,156,527,450,306,88,66],"class_list":["post-11067","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-biologic-exposed","scientific_tags-combination","scientific_tags-efficacy","scientific_tags-gma","scientific_tags-prospective","scientific_tags-refractory","scientific_tags-safety","scientific_tags-steroid","scientific_tags-tofacitinib","scientific_tags-ulcerative-colitis","scientific_tags-ustekinumab","scientific_tags-vedolizumab"],"acf":{"sc_authors":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/Supplement_1\/i1356\/7586745#google_vignette<\/a>"},"yoast_head":"\nP727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0 - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"P727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0 - Adacyte\" \/>\n<meta property=\"og:description\" content=\"E Papathanasiou\u00a0,\u00a0P Markopoulos\u00a0,\u00a0M Tzouvala\u00a0,\u00a0A Ioannou\u00a0,\u00a0E Tsironi\u00a0,\u00a0E Zacharopoulou\u00a0,\u00a0M Tzakri\u00a0,\u00a0E Pantelakis\u00a0,\u00a0G Leonidakis\u00a0,\u00a0G Bamias\u00a0,\u00a0S Michopoulos\u00a0,\u00a0E Zampeli Journal of Crohn’s and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1356\u2013i1357,\u00a0https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0857 Background: Selective depletion of myeloid lineage leucocytes by adsorptive granulocyte and monocyte apheresis (GMA) with Adacolumn\u00a0\u00ae\u00a0was introduced as a nonpharmacologic treatment for ulcerative colitis (UC) in 2000. It has […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T11:04:40+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/\",\"name\":\"P727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0 - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2024-01-07T11:59:00+00:00\",\"dateModified\":\"2025-08-08T11:04:40+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"P727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0 - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/","og_locale":"fr_FR","og_type":"article","og_title":"P727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0 - Adacyte","og_description":"E Papathanasiou\u00a0,\u00a0P Markopoulos\u00a0,\u00a0M Tzouvala\u00a0,\u00a0A Ioannou\u00a0,\u00a0E Tsironi\u00a0,\u00a0E Zacharopoulou\u00a0,\u00a0M Tzakri\u00a0,\u00a0E Pantelakis\u00a0,\u00a0G Leonidakis\u00a0,\u00a0G Bamias\u00a0,\u00a0S Michopoulos\u00a0,\u00a0E Zampeli Journal of Crohn’s and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1356\u2013i1357,\u00a0https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0857 Background: Selective depletion of myeloid lineage leucocytes by adsorptive granulocyte and monocyte apheresis (GMA) with Adacolumn\u00a0\u00ae\u00a0was introduced as a nonpharmacologic treatment for ulcerative colitis (UC) in 2000. It has […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/","og_site_name":"Adacyte","article_modified_time":"2025-08-08T11:04:40+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/","name":"P727 Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers\u00a0 - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2024-01-07T11:59:00+00:00","dateModified":"2025-08-08T11:04:40+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/p727-clinical-efficacy-of-apheresis-in-ulcerative-colitis-the-experience-of-four-tertiary-centers\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/11067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=11067"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=11067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}